The T-cell immunotherapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis 

Published: February 2023

Driven by high success rates in clinical trials and the potential to confer sustained periods of disease remission, T-cell therapies have received significant financial support, with approved products poised to soon achieve blockbuster status

Roots Analysis has announced the addition of Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition), 2022-2035” report to its list of offerings.

Having demonstrated the ability to selectively eradicate tumor cells from the body with minimal treatment-related side effects, a number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is anticipated to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

To order this 1,050+ page report, which features 390+ figures and 485+ tables, please visit this link

Key Market Insights 

Over 1,200 T-cell candidate therapies are currently approved / under development 
CAR-T cell products continue to dominate the clinical / preclinical pipeline, representing 77% of the total number of molecules, followed by TCR (15%) and TIL (8%) based therapies. Over 30% of the aforementioned candidates are in preclinical and discovery stages, while close to 10% are being evaluated in late clinical stages (phase II and above). 

Currently, the industry is focused on T-cell therapies targeting hematological malignancies
More than 90% of the products in the development pipeline are presently being developed to treat various types of cancers, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma and melanoma. On the other hand, only 3% of the pipeline candidates are being evaluated for the treatment of non-oncological indications.

Extensive efforts are underway to improve CAR constructs
Majority of the CAR-T cell therapies in clinical development, along with the six recently approved products, are based on second generation CARs. Further, lentivirus and retrovirus are presently the preferred type of vectors used for transduction of CAR constructs into T-cells. 

More than 49,470 patients have been enrolled in close to 960 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, more than 85% are active and still recruiting patients, while close 15% have already been completed.

Partnership activity within this domain has grown at a CAGR of 25%, between 2015 and 2022 
Since pre-2015, more than 430 agreements were inked related to T-cell therapies, with the maximum activity being reported in 2021. Majority of partnership deals signed within this domain were licensing agreements (26%), R&D agreements (24%), and product development and commercialization agreements (12%).

~ USD 30 billion has been invested by both private and public investors, across 330+ instances 
It is important to mention that, between pre-2018 and 2022, majority of the funding was acquired through venture capital rounds (42%), other equity financing elements (20%), secondary offerings (12%) and grants (12%).

6,820+ patents related to T-cell immunotherapies have been granted / filed between pre-2017- 2022
R&D activity related to T-cell immunotherapies is largely concentrated on development of CAR-T cell therapies, considering the fact that 96% of the total number of patents were filed for the aforementioned type of therapy. In addition, most of these patents are applications (84%), followed by granted patents (13%).

North America and Europe are anticipated to capture close to 75% of the market share by 2035
In addition, the market in China / broader Asia Pacific region is anticipated to grow at a relatively faster pace in the foreseen future. With a promising development pipeline and encouraging clinical results, CAR-T cell therapies is expected to capture the majority share (~73%) of the total market in 2035.  

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered
  • What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?
  • What kind of clinical conditions can be treated using T-cell immunotherapies?
  • Who are the leading industry and non-industry players in this market?
  • Across which key geographies, extensive research on T-cell immunotherapy is being conducted?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in the T-cell immunotherapy domain? 
  • Who are the key opinion leaders / experts from renowned academic and research institutes that can help drive product development efforts in this domain?
  • How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?
  • Who are the key service providers (CMOs / CDMOs) with the capabilities to develop and manufacture T-cell therapies?
  • What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the key promotional strategies used by companies for their marketed products?

The financial opportunity within the T-cell immunotherapies market has been analyzed across the following segments:

  • Type of Therapy
    • CAR-T cell therapy
    • TCR based therapy
    • TIL based therapy
  • Target Indication
    • Acute lymphoblastic leukemia
    • Non-Hodgkin’s lymphoma
    • Melanoma
    • Bladder cancer
    • Lung cancer
    • Head and neck cancer
    • Multiple myeloma
    • Sarcoma
    • Chronic lymphocytic leukemia
    • Ovarian cancer
    • Esophageal cancer
    • Colorectal cancer
    • Nasopharyngeal carcinoma
    • Hepatocellular carcinoma
    • Acute myeloid leukemia
    • Renal cell carcinoma
  • Target Antigen
    • CD19
    • BCMA
    • CD19/22
    • EGFR
    • NY-ESO-1
    • gp100
    • P53
    • EBV
    • MUC1
    • WT-1
    • Others
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and North Africa
    • Rest of the World 

The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

  • Tim Oldham (Former Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Former Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), T-cell based product(s), such as information on type of therapy and current development status, as technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the players. 

  • Adaptimmune Therapeutics
  • Alaunos Therapeutics
  • Autolus
  • bluebird Bio
  • Bristol Myers Squibb
  • Carsgen Therapeutics
  • Cellectis
  • Cellular Biomedicine Group
  • Gilead Sciences
  • GlaxoSmithKline
  • Immatics
  • Immunocore
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics
  • Kuur Therapeutics
  • Lion TCR
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Wellington Zhaotai Therapies
  • Zelluna immunotherapy 

For additional details, please visit

or email

You may also be interested in the following titles: 

  1. Novel Antibody Therapies Market, 2022- 2035
  2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035
  3. Gene Therapy Market (5th Edition), 2022-2035 

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry